VYNE Therapeutics Inc. (NASDAQ:VYNE) Short Interest Down 27.6% in January

VYNE Therapeutics Inc. (NASDAQ:VYNE) was the recipient of a significant decrease in short interest in the month of January. As of January 30th, there was short interest totaling 544,777 shares, a decrease of 27.6% from the January 15th total of 752,574 shares. Approximately 1.7% of the shares of the stock are sold short. Based on an average daily volume of 520,008 shares, the short-interest ratio is presently 1.0 days. Based on an average daily volume of 520,008 shares, the short-interest ratio is presently 1.0 days. Approximately 1.7% of the shares of the stock are sold short.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on VYNE shares. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of VYNE Therapeutics in a research note on Wednesday, January 21st. Wall Street Zen upgraded shares of VYNE Therapeutics from a “sell” rating to a “hold” rating in a report on Monday, February 2nd. Three investment analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Reduce” and an average price target of $4.50.

VYNE Therapeutics Stock Performance

NASDAQ VYNE opened at $0.57 on Monday. VYNE Therapeutics has a twelve month low of $0.28 and a twelve month high of $2.94. The stock has a market cap of $18.98 million, a price-to-earnings ratio of -0.73 and a beta of 2.02. The firm’s 50 day moving average price is $0.54 and its two-hundred day moving average price is $0.42.

Hedge Funds Weigh In On VYNE Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the business. Nantahala Capital Management LLC purchased a new position in VYNE Therapeutics during the fourth quarter valued at approximately $580,000. T3 Companies LLC purchased a new position in shares of VYNE Therapeutics during the 4th quarter valued at $548,000. Baker BROS. Advisors LP purchased a new position in shares of VYNE Therapeutics during the 3rd quarter valued at $285,000. Adage Capital Partners GP L.L.C. grew its stake in VYNE Therapeutics by 87.2% in the second quarter. Adage Capital Partners GP L.L.C. now owns 644,134 shares of the company’s stock valued at $1,063,000 after purchasing an additional 300,000 shares in the last quarter. Finally, Kennedy Capital Management LLC acquired a new position in VYNE Therapeutics in the 2nd quarter worth about $942,000. Hedge funds and other institutional investors own 83.78% of the company’s stock.

About VYNE Therapeutics

VYNE Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies for vascular, inflammatory and fibrotic diseases. The company is advancing a pipeline of selective oral inhibitors that modulate key pathways implicated in chronic tissue damage and immune dysregulation. Headquartered in the San Francisco Bay Area, VYNE Therapeutics seeks to address high-unmet-need conditions by leveraging proprietary chemical and biological insights to create differentiated drug candidates.

The company’s lead program, VTX-002, targets the colony-stimulating factor-1 receptor (CSF-1R) pathway, which plays a central role in macrophage proliferation and activation.